Inventor · disambiguated record
Jens Bo Rode Hansen
Also filed as: HANSEN JENS · HANSEN JENS B · HANSEN JENS BO · HANSEN JENS BO RODE
8 granted patents·10 pending applications·773 citations·filing 1995–2013
90Inventor score
Files withSANTARIS PHARMA AS5GS DEV AB2HANSEN JENS BO RODE2ROSENBOHM CHRISTOPH2ENZON PHARMACEUTICALS1
Top patents by PatentIndex Score
18 records- 0195US7741309B2Oligomeric compounds for the modulation of survivin expressionENZON PHARMACEUTICALS·Filed 2009·Granted Jun 22, 2010·120 cites·12 claims
- 0295US5955502AUse of fatty acid esters as bioadhesive substancesGS DEV AB·Filed 1997·Granted Sep 21, 1999·277 cites·22 claims
- 0394US7622453B2Oligomeric compounds for the modulation of Bcl-2SANTARIS PHARMA AS·Filed 2004·Granted Nov 24, 2009·114 cites·57 claims
- 0494US6228383B1Use of fatty acid esters as bioadhesive substancesGS DEV AB·Filed 1995·Granted May 8, 2001·196 cites·24 claims
- 0593US8580756B2Short oligomer antagonist compounds for the modulation of target mRNAHANSEN JENS BO RODE·Filed 2008·Granted Nov 12, 2013·52 cites·17 claims
- 0687US8026355B2Oligomeric compounds for the modulation of survivin expressionSANTARIS PHARMA AS·Filed 2010·Granted Sep 27, 2011·10 cites·9 claims
- 0775US8470791B2RNA antagonist compounds for the inhibition of Apo-B100 expressionHANSEN HENRIK FRYDENLUND·Filed 2008·Granted Jun 25, 2013·3 cites·28 claims
- 0862US8173428B2LNA oligonucleotides and the treatment of cancerROSENBOHM CHRISTOPH·Filed 2008·Granted May 8, 2012·1 cites·2 claims
- 0950US2006154888A1LNA oligonucleotides and the treatment of cancerSANTARIS PHARMA AS·Filed 2005·Application pending·0 cites
- 1049US2011224281A1Rna antagonists targeting hsp70-2HOG ANJA MOLHART·Filed 2009·Application pending·0 cites
- 1149US2010323967A1RNA Antagonist Compounds for the Modulation of MCL-1SANTARIS PHARMA AS·Filed 2008·Application pending·0 cites
- 1248US2011172292A1Antidote oligomersHANSEN JENS BO RODE·Filed 2009·Application pending·0 cites
- 1345US2012322848A1Lna oligonucleotides and the treatment of cancerROSENBOHM CHRISTOPH·Filed 2012·Application pending·0 cites
- 1442US2015315595A1Compositions and Methods for Modulation of ATXN3 ExpressionSANTARIS PHARMA AS·Filed 2013·Application pending·0 cites
- 1542US2005181978A1Therapeutic use of factor XIFiled 2004·Application pending·0 cites
- 1639US2007167488A1Novel therapeutic useLEO PHARMA AS·Filed 2004·Application pending·0 cites
- 1735US2010249219A1Short rna antagonist compounds for the modulation of hif-1alphaHEDTJAERN MAJ·Filed 2010·Application pending·0 cites
- 1834US2009113561A1Gene trap cassettes for random and targeted conditional gene inactivationFRANKGEN BIOTECHNOLOGIE AG·Filed 2005·Application pending·0 cites
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →